Finding | Cumulative incidence | Relevance | ||||||
Patient rate % (95% CI) n/N* | Endoscopy rate % (95% CI) n/N† | Biopsy rate % (95% CI) n/N | FU‡; Years Median (P25–P75) | FU‡, N endoscopies Median (P25–P75) | Reproduced % (95% CI) n/N | Progression to LGD/HGD/EAC % (95% CI) n/N | Progression to HGD/EAC % (95% CI) n/N | |
NSE random biopsies | ||||||||
Buried IM | 2.7 (1.5 to 4.8) (10/376) | 1.1 (0.6 to 2.0) (10/924) | 0.1 (0.1 to 0.2) (10/8588) | 4 (4 to 5) | 4 (4 to 5) | 0 (0 to 3.4) (0/10) | 0 (0 to 3.4) (0/10) | 0 (0 to 3.4) (0/10) |
Cardia random biopsies | ||||||||
IM | 13.8 (11.5 to 15.5) (150/1121) | 7.2 (6.3 to 8.3) (198/2733) | NA | 3 (2 to 4) | 3 (2 to 4) | 33.3 (25.8 to 41.8) (43/129)§ | 2.3 (0.1 to 7.2) (3/129) | 0 (0 to 2.9) (0/129) |
LGD | 0.81 (0.42 to 1.5) (9/11 121) | 0.73 (0.46 to 1.15) (20/2733) | NA | 2 (2 to 5) | 2 (2 to 4) | 75.0 (35.6 to 95.6) (6/8)¶ | NA | 0 (0 to 40.2) (0/8) |
The diagnostic yield of random biopsies from NSE and cardia and long-term follow-up of abnormal findings.
*N = patients with at least 1 endoscopy with sampling from NSE or cardia.
†N = Endoscopies with sampling from NSE or cardia.
‡Median FU after detection of buried BE; IM; of LGD.
§N=patients with IM in the cardia; either at end of treatment (n=78) or during FU (n=72). Patients with treatment (n=9) or no FU (n=12) were excluded.
¶A single patient underwent additional RFA and was not included for the FU analysis.
**Adjusted for potential confounders age, gender, length of BE, worst pathology at baseline, reflux stenosis, incident lesion.
BE, Barrett’s oesophagus; IM, intestinal metaplasia; LGD, low-grade dysplasia; NSE, neosquamous epithelium; RBx, random biopsies; RFA, radiofrequency ablation.